

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A stable and easy to formulate amorphous solid, suitable for the preparation of solid pharmaceutical compositions, the amorphous solid comprising a mixture of an amorphous active pharmaceutical ingredient and at least one amorphous pharmaceutically acceptable inactive ingredient.

2. (Currently Amended) The stable, amorphous solid ~~mixture~~ of claim 1, wherein the active pharmaceutical ingredient is selected from the group consisting of donepezil hydrochloride and losartan potassium.

3. (Currently Amended) The stable, amorphous solid ~~mixture~~ of claim 1, wherein the inactive ingredient is selected from the group consisting of lactose, polyvinylpyrrolidone and polyethylene glycol and mixtures thereof.

4. (Currently Amended) The stable, amorphous solid ~~mixture~~ of claim 1, wherein the ratio of inactive to active ~~components of said mixture~~ ingredients is in the range of from about 10/1 to about 0.3/1.

5. (Currently Amended) The stable, amorphous solid ~~mixture~~ of claim 1, wherein the ratio of inactive to active ~~components of said mixture~~ ingredients is in the range of from about 3/1 to about 1/1.

6. (Currently Amended) The stable, amorphous solid ~~mixture~~ of claim 1, wherein the ratio of inactive to active ~~components of said mixture~~ ingredients is ~~in the range of~~ about 3/1.

7. (Currently Amended) The stable, amorphous solid ~~mixture~~ of claim 1, wherein the ratio of inactive to active ~~components of said mixture~~ ingredients is ~~in the range of~~ about 1/1.

8. (Currently Amended) The stable, amorphous solid ~~mixture~~ of claim 1 wherein the

active ingredient is donepezil hydrochloride, the inactive ingredient is lactose and the lactose/donepezil hydrochloride ratio is about 3/1.

9. (Original) The stable, amorphous solid ~~mixture~~ of claim 1 made by lyophilization.

10 - 13. (Canceled)

14. (Currently Amended) A solid pharmaceutical composition comprising a the stable solid amorphous mixture ~~as claimed in~~ of claim 1 ~~in combination with~~ and a pharmaceutically acceptable carrier.

15 - 18. (Canceled)

19. (New) The stable, amorphous solid of claim 1 in the form of a flowing powder.

20. (New) The stable, amorphous solid of claim 4, wherein the inactive ingredient is lactose and the active ingredient is donepezil hydrochloride.

21. (New) The stable, amorphous solid of claim 5, wherein the inactive ingredient is lactose and the active ingredient is donepezil hydrochloride.